Afatinib plus bevacizumab treatment for a patient with EGFR S645C-mutant NSCLC

Abstract

Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) improve the survival outcomes of patients with advanced lung adenocarcinoma with common mutations. However, challenges persist in treating rare, uncommon EGFR mutations, such as EGFR S645C, which accounts for only 0.011% of the EGFR mutations in the Guardant360 database. Despite preclinical studies indicating its resistance to osimertinib, we present a case of using afatinib plus bevacizumab to successfully treat a patient with EGFR S645C mutation, for which an effective treatment had not been previously reported. This case report presents real-world evidence for optimal therapeutic options for patients with EGFR S645C mutation.